Cabazitaxel alone, abiraterone alone, or both one after another slowed prostate cancer progression after docetaxel

[JimJimJimJim]

Jim Marshall (not a doctor) said ...

 

Cabazitaxel used alone, and abiraterone used alone slowed prostate cancer progression in castrate resistant men who had failed taxotere. Having both, one after another, worked better. There were too few men in the trial to tell which was better to have first.

Months to progression:

Abiraterone alone 8.6 months
Cabazitaxel alone 4.7 months
Cabazitaxel then abiraterone 8.2 + 5.6 = 13.8 months
Abiraterone then cabazitaxel 8.2 + 4.0 = 12.2 months

... end Jim

Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).

This abstract is only available for 24 hours for members to get an email.

After 24 hours the abstract will only be available through the link to the ASCO site below.

 

Caution
This extract was published in association with the American Society of Clinical Oncology 2013 annual conference. Though the research behind it may have been excellent, your doctor cannot yet give much weight to it for a number of reasons, including:

• It is only an extract. The full paper may reveal information important for your treatment.
• The study has not yet had peer review - with doctors and researchers scrutinising the study closely for mistakes and limitations after it is published in a professional journal.
•  Your doctor may already be aware of a limitations of the findings because of their wider reading.

The link below is to a page or document that we do not control.
Parts of it may be wrong or misleading.
Check with your doctor if something interests you.
If it is temporarily or permanently unavailable, you may receive an error message.

 

 

Source URL: http://meetinglibrary.asco.org/content/114827-132